18F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma.
Geoffrey Michael CurrieMarko TrifunovicJui LiuSang KimHoward GurneyPublished in: Journal of nuclear medicine technology (2021)
Targeted molecular imaging with positron emission tomography (PET) utilize chemical ligands is a peptide that specifically targets a receptor of interest. Prostate specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. This teaching case provides an insight incidental detection of RCC metastatic disease with PSMA targeted PET and explores potential in deliberate evaluation of RCC with PSMA targeted tracers.
Keyphrases
- pet ct
- renal cell carcinoma
- positron emission tomography
- prostate cancer
- cancer therapy
- metastatic renal cell carcinoma
- squamous cell carcinoma
- small cell lung cancer
- radical prostatectomy
- pet imaging
- computed tomography
- benign prostatic hyperplasia
- medical students
- drug delivery
- age related macular degeneration
- human health
- climate change
- endothelial cells